Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent cushing's syndrome

Hormone and Metabolic Research

Volumn 43, Issue 4, 2011, Pages 287-291

  Preumont, V ^a   Mermejo, L M ^b   Damoiseaux, P ^c   Lacroix, A ^b   Maiter, D ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Centre Hospitalier de Dinant   (Belgium)

Author keywords

GIP dependent Cushing's syndrome; octreotide; pasireotide

Indexed keywords

ANTIHYPERTENSIVE AGENT; CORTICOTROPIN; GLICLAZIDE; HYDROCORTISONE; INSULIN; METFORMIN; OCTREOTIDE; PASIREOTIDE;

ADRENAL HYPERPLASIA; ADRENALECTOMY; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CASE REPORT; CONTROLLED STUDY; CUSHING SYNDROME; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG EFFICACY; DYSLIPIDEMIA; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; MOON FACE; MUSCLE ATROPHY; OBESITY; PRIORITY JOURNAL; SKIN BRUISING; STEROID BLOOD LEVEL;

ADRENALECTOMY; CUSHING SYNDROME; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; MIDDLE AGED; OCTREOTIDE; RECEPTORS, GASTROINTESTINAL HORMONE; SOMATOSTATIN;

EID: 79953277874     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1270523     Document Type: Article

References (17)

1. Lacroix A, Bourdeau I, Lampron A, Mazzuco TL, Tremblay J, Hamet P. Aberrant G-protein coupled receptor expression in relation to adrenocortical overfunction. Clin Endocrinol 2010 73 1-15
2. Lacroix A, N'Diaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing's syndrome. Endocr Rev 2001 22 75-110 (Pubitemid 32187804)
3. Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, Lebrethon MC, Budi I, Balliere AM, Mahoudeau J. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992 327 981-986
4. Lacroix A, Bourdeau I. Bilateral adrenal Cushing's syndrome: macronodular adrenal hyperplasia and primary pigmented nodular adrenocortical disease. Endocrinol Metab Clin North Am 2005 34 441-458 (Pubitemid 40602731)
5. Lacroix A, Mircescu H, Hamet P. Clinical evaluation of the presence of abnormal hormone receptors in adrenal Cushing's syndrome. Endocrinologist 1999 9 9-15 (Pubitemid 29108934)
6. Lampron A, Bourdeau I, Oble S, Godbout A, Schurch W, Arjane P, Hamet P, Lacroix A. Regulation of aldosterone secretion by several aberrant receptors including for GIP in a patient with an aldosteronoma. J Clin Endocrinol Metab 2009 94 750-756
7. Zwermann O, Suttmann Y, Bidlingmaier M, Beuschlein F, Reincke M. Screening for membrane hormone receptor expression in primary aldosteronism. Eur J Endocrinol 2009 160 443-451
8. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001 29 e45
9. Hsiao HP, Kirschner S, Bourdeau I, Keil MF, Boikos SA, Verma S, Robinson-White AJ, Nesterova M, Lacroix A, Stratakis CA. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab 2009 94 2930-2937
10. De Miguel V, Redal MA, Viale ML, Kahan M, Glerean M, Beskow A, Fainstein Day P. Aberrant expression of glucagon receptors in adrenal glands of a patient with Cushing's syndrome and ATCH-independent macronodular adrenal hyperplasia. Medicina 2010 70 254-256
11. Libé R, Coste J, Guignat L, Tissier F, Lefebvre H, Barrande G, Ajzenberg C, Tauveron I, Clauser E, Dousset B, Bertagna X, Bertherat J, Groussin L. Aberrant cortisol regulations in bilateral macronodular adrenal hyperplasia: a frequent finding in a prospective study of 32 patients with overt or subclinical Cushing's syndrome. Eur J Endocrinol 2010 163 129-138
12. Joubert M, Louiset E, Do Rego JL, Contesse V, Kong LC, Benhaim A, Mittre H, Lefebvre H, Reznik Y, for the REHOS Study Group. Aberrant adrenal sensitivity to vasopressin in adrenal tumours associated with subclinical or overt autonomous hypercortisolism: is this explained by an overexpression of vasopressin receptors. Clin Endocrinol 2007 68 692-699 (Pubitemid 351533441)
13. 1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. J Clin Endocrinol Metab 1997 82 2414-2422 (Pubitemid 27337849)
14. Arnaldi G, Gasc JM, de Keyzer Y, Raffin-Sanson ML, Perraudin V, Kuhn JM, Raux-Demay MC, Luton JP, Clauser E, Bertagna X. Variable expression of the V1 vasopressin receptor modulates the phenotypic response of steroid-secreting adrenocortical tumors. J Clin Endocrinol Metab 1998 83 2029-2035 (Pubitemid 28496333)
15. , receptor and coupling of ectopic receptors to protein kinase a and ionic currents in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome. J Clin Endocrinol Metab 2006 91 4578-4586 (Pubitemid 44833441)
16. Bruns C, Lewis I, Meno-Tetang G, Weckbecker G. SOM 230: a novel somatostatin peptidomimetic with broad somatropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002 146 707-716 (Pubitemid 34552506)
17. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Schmid KW, Mann K, Petersenn S. Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4 and 5 in various adrenal tumors. Endocr Res 2004 30 931-934 (Pubitemid 40070196)